|Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents - Monitor Patents|
USPTO Class 530 | Browse by Industry: Previous - Next | All
09/2009 | Recent | 13: May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof September class, title,number 09/09Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 09/24/2009 > patent applications in patent subcategories. class, title,number
20090240026 - Novel fluorescent amino acid derivative and production method of the same: An object of the present invention is to provide a novel fluorescent amino acid derivative which can be synthesized by simple steps, can be excited particularly by a blue laser ray region of visible light, and has an improved light stability. Another object is to provide a production method of... Agent: Kilyk & Bowersox, P.l.l.c.
20090240027 - Intermediates for macrocyclic compounds: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with... Agent: Myers Bigel Sibley & Sajovec
20090240028 - Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides: The invention provides synthesis and application of new structural well defined branched polymers as protraction agents for peptide and protein.... Agent: Novo Nordisk, Inc. Intellectual Property Department
20090240030 - Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry: This invention provides methods for covalently affixing a biomolecule to either a second molecule or a solid surface using 1,3-dipolar cycloaddition chemistry. This invention also provides related methods and compositions.... Agent: Cooper & Dunham, LLP
20090240029 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.
20090240033 - Affinity matrix library and its use: The invention relates, at least in part, to an affinity matrix library and the construction and use thereof. The library may be used, for example, for the enrichment of low-abundance proteins and depletion of abundant proteins in the search for biologically important proteins. The present invention also relates to a... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000
20090240032 - Novel sugar-immobilized metal nanoparticle, method for measuring sugar-protein interaction using the same and method for recovering protein from sugar-protein interactant: It is intended to provide a stable novel sugar-immobilized metal nanoparticle capable of easily immobilizing a sugar chain, a method for measuring sugar-protein interaction easily and at a low cost using the same without labeling, and a method for simply recovering a protein from a sugar-protein interactant. A maltose-immobilized gold... Agent: Morrison & Foerster LLP
20090240031 - Process and intermediate products for preparing cardiodilatin fragments, and highly purified cardiodilatin fragments: The invention relates to a process for the preparation of cardiodilatin fragments, to highly purified cardiodilatin fragments, and to appropriate intermediates for the preparation of said fragments. Furthermore, the invention relates to highly purified cardiodilatin fragments which are free of peptide impurities and exhibit a single migration peak in capillary... Agent: Patent Docket Administrator Lowenstein Sandler PC
20090240034 - Method for producing peptide thioester: It is an object of the present invention to provide a novel method for producing a peptide thioester. In the present invention, general peptide synthesis is performed on a solid-phase resin, carboxylic acid obtained after cutout is allowed to react with p-toluenesulfonyl isocyanate, and then the reaction product is alkylated,... Agent: Greenblum & Bernstein, P.L.C
20090240035 - Dna replication proteins of gram positive bacteria and their use to screen for chemical inhibitors: The present invention relates to alpha-large, alpha-small, delta, delta prime, tau, beta, SSB, DnaG, and DnaB encoding genes from Gram positive bacterium, preferably Streptococcus and Staphylococcus bacterium. The formation of functional polymerase as well as the use of such a polymerase in sequencing and amplification is also disclosed. The individual... Agent: Nixon Peabody LLP - Patent Group
20090240036 - Anti-il-23 antibodies: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.... Agent: Eli Lilly & Company
20090240037 - Humanized antibodies and methods of humanizing antibodies: Humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which are useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis are disclosed. Methods... Agent: Rossi, Kimms & Mcdowell LLP.
20090240038 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and... Agent: Knobbe Martens Olson & Bear LLP
20090240039 - Polypeptide fusion: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-β and TPO, linked to a subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw
20090240040 - Purification of a bivalently active antibody using a non-chromatographic method: The present invention discloses a method of purifying bivalent antibodies or antibody fragments that are active at both Fab sites from a source of antibodies or antibody fragments using a non-chromatographic method that includes inducing the formation of cyclic immunoglobulin aggregates by addition of multivalent hapten to a salt solution... Agent: Wilmerhale/boston09/17/2009 > patent applications in patent subcategories. class, title,number
20090234096 - Influenza inhibiting compositions and methods: The present invention provides compositions useful for treating or preventing influenza infections. The composition comprises an isolated polypeptide including a sequence of at least 8 contiguous amino acid residues of the fusion initiation region (FIR) of an influenza hemagglutinin 2 protein or a peptide analog of the sequence. The FIR... Agent: Olson & Cepuritis, Ltd.
20090234098 - Method of preparing peptide: The present invention provides a method of preparing an intermediate for LHRH antagonists, which requires fewer steps than conventional methods and provides the intermediate in high yield and high purity.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.
20090234097 - Vasodilator: There is provided a vasodilator having an endothelium-dependent vasodilator effect, a prophylactic of arteriosclerosis, and functional food having an endothelium-dependent vasodilator effect, which is suitable for daily and regular intake and excellent in safety. The vasodilator and the functional food according to the present invention are characterized in at least... Agent: Sughrue Mion, PLLC
20090234099 - Purification of peptides from colostrum: The invention relates to the purification of peptides from colostrum. The method involves the addition of an alcohol such as methanol or ethanol to the mixture in order to form an alcohol phase rich in the peptides, and a precipitate. The peptide-rich alcohol phase is subsequently recovered and subjected to... Agent: Rankin, Hill & Clark LLP
20090234101 - Directed evolution of novel binding proteins: In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore... Agent: Dyax Corp. C/o Wolf, Greenfield & Sacks, P.C.
20090234100 - Osteogenic compositions comprising an amiono acid sequence which is capable of being phosphorylated by camk2: Novel osteogenic compositions and methods are provided. In a broad aspect, the composition comprises either a first amino acid sequence which is capable of being phosphorylated by CAMK2; or a nucleic acid sequence encoding the first amino acid sequence; or a combination thereof. Optionally, the first amino acid sequence may... Agent: Fox Rothschild LLP Princeton Pike Corporate Center
20090234102 - Hepatitis c virus inhibitors: v
20090234105 - Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition: The present invention provides for a practical, universal and efficient method to ligate two large macromolecules (e.g., proteins) using the alkyne-azide 1,3-dipolar cycloaddition reaction to produce a conjugated macromolecule, such as a multivalent scFv. The present invention also provides for conjugate macromolecules comprising a plurality of macromolecule components cross-linked through... Agent: Townsend And Townsend And Crew, LLP
20090234104 - Modified fc molecules: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.... Agent: Amgen Inc.
20090234103 - Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial... Agent: Jones Day
20090234106 - Anti-activin a antibodies and uses thereof: The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such... Agent: Davis Wright Tremaine, LLP/seattle
20090234107 - Protein-immobilized carrier: The present invention provides a protein-immobilized carrier which can realize highly efficient use of an immobilized antibody and prevent non-specific binding. A protein-immobilized carrier including a porous body having mesopores characterized in that the carrier has mesopores having an organic substance adsorbed therein other than an antibody, an antigen or... Agent: Fitzpatrick Cella Harper & Scinto
20090234108 - Multivalent pneumococcal polysaccharide-protein conjugate composition: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic... Agent: Alston & Bird LLP09/10/2009 > patent applications in patent subcategories. class, title,number
20090227766 - Biomass pyrolysis: A process for pyrolysing biomass is provided. The process comprises providing biomass to a pyrolysis reactor to produce a vapour product and condensing said vapour product to produce a condensed product, wherein a phase separation suppression agent is added during said process so as to promote the formation of a... Agent: Leason Ellis LLP
20090227767 - Process for producing tall oil and use of heating in the production of tall oil: The invention relates to a process for the production of tall oil from soap oil and to the use of heating in order to improve the production of tall oil. Soap oil, which has been produced by neutralization of tall oil soap, is acidulated by reacting the soap oil with... Agent: Arent Fox LLP
20090227768 - Anti-allergic complex molecules: The present invention discloses novel anti-allergic complex molecules, and in particular, peptidic or peptidomimetic molecules, that includes a first part which is competent for cell penetration and a second part which is able to reduce or abolish mast cell degranulation, in particular to reduce or abolish allergy mediators, including histamine... Agent: Townsend And Townsend And Crew, LLP
20090227769 - Cftr with a partially deleted r domain and uses thereof: The present invention offers new therapies for treating Cystic Fibrosis (CF), that are based on novel DNA molecules and proteins encoded by the DNA molecules. The present invention features DNA molecules encoding CFTR having a partially deleted R domain. The partial deletions in the R domain are between residues 708... Agent: Mckee, Voorhees & Sease, P.L.C
20090227771 - Grg23 and grg51 genes conferring herbicide resistance: Compositions and methods for conferring herbicide resistance or tolerance to bacteria, plants, plant cells, tissues and seeds are provided. Compositions include polynucleotides encoding herbicide resistance or tolerance polypeptides, vectors comprising those polynucleotides, and host cells comprising the vectors. The nucleotide sequences of the invention can be used in DNA constructs... Agent: Alston & Bird LLP
20090227770 - Polypeptide carrier protein: The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated... Agent: Novartis Vaccines And Diagnostics Inc.
20090227772 - Human gil-19/ae289 proteins and polynucleotides encoding same: Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.... Agent: Wyeth/latimer, Mayberry & Matthews, LLP
20090227773 - Process for the production of collagen material: The invention relates to a process for the production of a collagen implant for wound covering, in which a suspension comprising a telopeptide-containing collagen is produced and a phosphate buffer is added. An areal structure is produced by drying the collagen-containing mixture produced.... Agent: Demont & Breyer, LLC
20090227774 - Polyhedral nanostructures formed from nucleic acids: The present invention provides a nucleic acid polyhedron having a moiety associated therewith together with methods of making the nucleic acid polyhedron.... Agent: Clark & Elbing LLP
20090227775 - Hiv inhibiting proteins: The invention relates to proteins comprising HIV fusion inhibiting peptides, such as T-20 and/or T-1249 peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins exhibit extended shelf-life and/or extended... Agent: Ballard Spahr Andrews & Ingersoll, LLP
20090227776 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Goodwin Procter LLP Attn: Patent Administrator
20090227777 - Monoclonal antibody for hippuric acid antigen: Provided is a monoclonal antibody specific for hippuric acid which is one of the representative harmful hallucinogenic substances and is the major metabolite of toluene. In the present invention, a hippuric acid-carrier protein conjugate is prepared from hippuric acid and BSA or OVA as a carrier protein, using a coupling... Agent: Christie, Parker & Hale, LLP
20090227778 - Stable cell lines expressing herg1a and herg1b: A line of cultured mammalian cells includes HERG1b subunits and optionally HERG1a subunits.... Agent: Quarles & Brady LLP
20090227779 - Dry hemostatic compositions and methods for their preparation: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has... Agent: Baxter Healthcare Corporation09/03/2009 > patent applications in patent subcategories. class, title,number
20090221789 - Crystalline polypeptides: Crystalline formulations of therapeutic peptides, along with methods for making and using the same, are provided.... Agent: Amgen Inc.
20090221790 - Method for stabilization of proteins using non-natural amino acids: y
20090221791 - Composition and method for the release of protected peptides from a resin: The present invention provides a composition and a method for cleaving a peptide from a solid support resin. Hydrochloric acid in an organic water miscible solvent is used to cleave the peptide-resin attachment. Optionally, trifluoroethanol or hexafluoroisopropanol may be added to the cleavage composition to improve results. When using the... Agent: Mallinckrodt Inc.
20090221792 - Microwave-assisted peptide synthesis: An instrument and associated method are disclosed for the accelerated synthesis of peptides by the solid phase method. The instrument includes a microwave cavity, a microwave source in communication with the cavity, a column in the cavity formed of a material that is transparent to microwave radiation, a solid phase... Agent: Summa, Additon & Ashe, P.A.
20090221793 - Process for preparing a pentopyranosyl nucleic acid conjugate: The invention relates to a process for preparing a conjugate that includes a pentopyranosyl nucleic acid and a biomolecule. The process includes the steps of providing a pentopyranosyl nucleic acid having at least two pentopyranosyl nucleotide subunits that are covalently linked between carbon 4 and carbon 2 of their respective... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7
20090221795 - Active truncated form of the rna polymerase of flavivirus: The isolation and purification of two domains from a from a flavivirus is provided. Each domain can function independently. Moreover, one domain codes for a sequence that provide polymerase activity. A process for screening possible modulators of the polymerase activity of an isolated and purified polypeptide from flavivirus is also... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.
20090221796 - Heteromeric taste receptors: Heteromeric taste receptors are provided. These receptors comprise a first polypeptide containing extracellular domains and transmembrane domains wherein the extracellular domains are at least 95% identical to the extracellular domains of specific T1R2 polypeptides and the transmembrane domains are at least 95% identical to the corresponding transmembrane domains of the... Agent: Hunton & Williams LLP Intellectual Property Department
20090221797 - Heteromeric taste receptors: Heteromeric taste receptors are provided. These receptors comprise a first polypeptide which comprises extracellular and transmembrane domains wherein the transmembrane domains are at least 95% identical to the transmembrane domains of specific T1R1 polypeptides, and the extracellular domains are at least 95% identical to the corresponding extracellular domains of the... Agent: Hunton & Williams LLP Intellectual Property Department
20090221798 - Heteromeric taste receptors: Heteromeric taste receptors are provided. These receptors comprise a first polypeptide which comprises extracellular and transmembrane domains wherein the transmembrane domains are at least 95% identical to the transmembrane domains of specific T1R2 polypeptides, and the extracellular domains are at least 95% identical to the corresponding extracellular domains of the... Agent: Hunton & Williams LLP Intellectual Property Department
20090221794 - Human protooncogene and protein encoded by same: Disclosed are a novel protooncogene and a protein encoded by the same. The protooncogene of the present invention may be effectively used for diagnosing various cancers including breast cancer, leukemia, uterine cancer, malignant lymphoma, etc.... Agent: Sughrue Mion, PLLC
20090221799 - Novel fluorescent and colored proteins, and polynucleotides that encode these proteins: The subject invention provides new fluorescent and/or colored proteins, and polynucleotide sequences that encode these proteins. The subject invention further provides materials and methods useful for expressing these detectable proteins in biological systems.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20090221800 - Method for the production of recombinant proteins: The present invention relates to a process for the production of recombinant polypeptides in leukocytes.... Agent: Novo Nordisk, Inc. Intellectual Property Department
20090221801 - Adsorbents for protein purification: Use of an affinity adsorbent for the separation, removal, isolation, purification, characterisation, identification or quantification of a proteinaceous material, wherein the affinity adsorbent is a compound of formula (III), wherein R1 is H, alkyl, aryl, hydroxyalkyl, cyciohexyl, amino or a heterocyclic group which is optionally substituted with one or more... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20090221803 - Modulation of antibody effector function by hinge domain engineering: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc... Agent: Medimmune, LLC Jonathan Klein-evans
20090221802 - Soluble zalpha11 cytokine receptors: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding... Agent: Zymogenetics, Inc. Intellectual Property Department
20090221804 - Gbs toxin receptor compositions and methods of use: Methods are provided for preventing or attenuating pathoangiogenic conditions by administering at least one GBS toxin receptor polypeptide or at least one immunogenic fragment thereof. Also provided are a composition that includes a GBS toxin receptor polypeptide and a method for making such a composition. In another embodiment of the... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP
20090221805 - Complex polymere amphiphile-pdgf: Physically and chemically stable, water-soluble, amphiphilic polymer-PDGF complex, characterized in that the amphiphilic polymers include a hydrophilic polymeric backbone functionalized with hydrophobic substituents and hydrophilic groups.... Agent: Oliff & Berridge, PLCPrevious industry: Synthetic resins or natural rubbers -- part of the class 520 series
Next industry: Organic compounds -- part of the class -570 series
RSS FEED for 20130516:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents we recommend signing up for free keyword monitoring by email.
FreshPatents.com Support - Terms & Conditions
Results in 0.39556 seconds